CTTC Stock Overview
Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Calmare Therapeutics Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.025 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | -90.00% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| CTTC | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | 1.2% |
| 1Y | n/a | -0.5% | 24.9% |
Return vs Industry: Insufficient data to determine how CTTC performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how CTTC performed against the US Market.
Price Volatility
| CTTC volatility | |
|---|---|
| CTTC Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CTTC's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CTTC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | n/a | Conrad Mir | www.calmaretherapeutics.com |
Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014.
Calmare Therapeutics Incorporated Fundamentals Summary
| CTTC fundamental statistics | |
|---|---|
| Market cap | US$38.00 |
| Earnings (TTM) | -US$3.83m |
| Revenue (TTM) | US$1.14m |
0.0x
P/S Ratio0.0x
P/E RatioIs CTTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTTC income statement (TTM) | |
|---|---|
| Revenue | US$1.14m |
| Cost of Revenue | US$373.29k |
| Gross Profit | US$771.48k |
| Other Expenses | US$4.60m |
| Earnings | -US$3.83m |
Last Reported Earnings
Dec 31, 2016
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CTTC perform over the long term?
See historical performance and comparison